• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $EVAX

    Evaxion Biotech A/S

    Subscribe to $EVAX
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Evaxion Biotech A/S, a clinical-stage artificial intelligence-immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. The company develops therapies using PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform. It develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase I/IIa trial for indications, such as metastatic and/or unresectable melanoma, non-small cell lung cancer, and bladder cancer; EVX-02, a novel, DNA-based cancer immunotherapy that is in Phase I/IIa trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, a DNA-based neoepitope immunotherapy, which is in late pre-clinical development for the treatment of various cancers, as well as EVX-B1, a multi-component subunit vaccine, which is in pre-clinical development for the prevention of S. aureus induced skin and soft tissue infections in patients undergoing hernia surgery. The company has collaboration agreements with National Center for Cancer Immune Therapy (CCIT-DK) at Herlev Hospital, Department of Health Technology at Danish Technical University, Center for Genomic Medicine at University Hospital Copenhagen, and the Center for Vaccine Research at SSI for the development and Phase 1/2a clinical trial of its EVX-01 product candidate. Evaxion Biotech A/S was incorporated in 2008 and is headquartered in Hoersholm, Denmark.

    IPO Year: 2021

    Exchange: NASDAQ

    Website: evaxion-biotech.com

    Peers

    $BBI
    $SQZ

    Recent Analyst Ratings for Evaxion Biotech A/S

    DatePrice TargetRatingAnalyst
    4/2/2024$8.00Neutral → Buy
    Ladenburg Thalmann
    2/12/2024$14.00Buy
    H.C. Wainwright
    See more ratings

    Evaxion Biotech A/S Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting

      80% of EVX-01 vaccine targets triggered a tumor-specific immune response, a substantially higher frequency than what has been reported for other similar vaccine candidatesThe data underscores the precision of Evaxion's AI-Immunology™ platform in selecting therapeutically relevant vaccine targetsNew findings show EVX-01 inducing a robust and durable immune response, further enhanced by booster immunizationsThe ongoing phase 2 trial with EVX-01 remains on track for two-year data readout in the second half of 2025COPENHAGEN, Denmark, April 28, 2025 - Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announ

      4/28/25 8:00:41 AM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Evaxion announces business update and full year 2024 financial results

      COPENHAGEN, Denmark, April 1, 2025 - Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces full year 2024 financial results.Business highlights2024 and the first months of 2025 saw Evaxion make substantial progress in both business development, research and development and financing. Key highlights are listed below.Our transformational partnership with MSD (Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA) on two vaccine candidates for infectious diseases entered in September 2024. The projects are tracking according to the agreed plans towar

      4/1/25 7:30:35 AM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Evaxion to announce business update and full year 2024 financial results on April 1, 2025

      COPENHAGEN, Denmark, March 27, 2025 - Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its full year 2024 financial results on Tuesday April 1, 2025, before opening of the Nasdaq CM.Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, open to the public and encouraged.To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numb

      3/27/25 8:00:21 AM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

      New biomarker and immune data from the ongoing phase 2 trial with EVX-01 will be presented at the American Association for Cancer Research (AACR) Annual Meeting These data will further add to the already strong clinical data package for EVX-01The trial remains on track for two-year clinical efficacy data readout in the second half of 2025COPENHAGEN, Denmark, March 25, 2025 - Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present new data for its lead asset EVX-01 at a poster session at the American Association for Cancer Research (AACR) Annual Meeting taking place in Chicago April 25-30, 2025. D

      3/25/25 4:30:39 PM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Evaxion to present at numerous upcoming conferences

      Evaxion will provide company and scientific updates at conferences in both the US and Europe during the coming weeks and months COPENHAGEN, Denmark, March 4, 2025 - Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting at several investor and scientific conferences in March and throughout the second quarter of 2025. Evaxion will be providing company and scientific updates as well as engaging with different stakeholders at conferences in both the US and Europe. As such, conference participation is an important part of our strategy to identify potential partners and opportunities for both

      3/4/25 8:00:00 AM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

      Originally planned as a two-year study, the trial has been extended by an additional year to collect three-year clinical outcome data The additional third year of EVX-01 dosing may provide further insights into potential enhanced treatment effects and durability of induced immune response The trial already yielded convincing one-year data and remains on track for two-year data readout in the second half of 2025 COPENHAGEN, Denmark, February 25, 2025 - Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will further enhance the data package from its ongoing phase 2 trial with the company's lead asset EVX-

      2/25/25 8:00:00 AM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Nasdaq confirms Evaxion is fully compliant, withdraws delisting determination

      Evaxion will remain listed on Nasdaq after successfully evidencing compliance with the Nasdaq minimum stockholders' equity requirement Evaxion has restored its equity above the minimum requirement through capital market activitiesEvaxion's cash runway now extends to mid-2026The conversion of Evaxion's EIB loan to equity is still expected to be completed in Q1 2025, which is anticipated to further boost equity COPENHAGEN, Denmark, February 14, 2025 - Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has received confirmation from the Nasdaq Stock Market LLC ("Nasdaq") that it has re-established complian

      2/14/25 8:00:00 AM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Evaxion announces closing of $10.8 million public offering

      COPENHAGEN, Denmark, January 31, 2025 - Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the closing of a public offering of an aggregate of 3,997,361 of its American Depositary Shares ("ADSs") and warrants to purchase up to 50% of the ADSs offered at a combined public offering price of $2.71 per ADS with one accompanying warrant for each two ADSs. MSD Global Health Innovation Fund, a corporate venture capital arm of Merck & Co., Inc., Rahway, NJ, USA, who became an Evaxion shareholder in December 2023, participated in this offering along with healthcare-focused investment funds. There

      1/31/25 4:05:00 PM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Evaxion announces pricing of $10.8 million public offering

      COPENHAGEN, Denmark, January 30, 2025 - Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the pricing of a public offering of an aggregate of 3,997,361 of its American Depositary Shares ("ADSs") and warrants to purchase up to 50% of the ADSs offered at a combined public offering price of $2.71 per ADS with one accompanying warrant for each two ADSs. MSD Global Health Innovation Fund, a corporate venture capital arm of Merck & Co., Inc., Rahway, NJ, USA, who became an Evaxion shareholder in December 2023, is also participating in this offering along with healthcare-focused investment fun

      1/30/25 8:00:00 AM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement

      Following a constructive Nasdaq hearing panel on January 7, 2025, Evaxion has been granted a 180-day extension in relation to the Nasdaq minimum equity requirementEvaxion has currently restored its equity above the minimum requirement through exercise of prefunded warrants and sales through its ATM-facility providing $7.8 million, extending its cash runway until Q4 2025The conversion of Evaxion's EIB-loan to equity is still expected to be completed in Q1, 2025, which is expected to boost equityEvaxion continues to see strong progress in ongoing business development discussions which is expected to further support equity going forward COPENHAGEN, Denmark, January 28, 2025 - Evaxion Biotech A

      1/28/25 8:15:00 AM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Evaxion Biotech A/S Financials

    Live finance-specific insights

    See more
    • Evaxion to announce business update and full year 2024 financial results on April 1, 2025

      COPENHAGEN, Denmark, March 27, 2025 - Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its full year 2024 financial results on Tuesday April 1, 2025, before opening of the Nasdaq CM.Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, open to the public and encouraged.To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numb

      3/27/25 8:00:21 AM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Evaxion to announce business update and third quarter 2024 financial results on October 31

      COPENHAGEN, Denmark, October 28, 2024 - Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its third quarter 2024 financial results on Thursday October 31, 2024, before opening of the Nasdaq CM.  Evaxion's Executive Management will host a conference call and webcast the same day at 13:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, open to the public and encouraged.  To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receiv

      10/28/24 8:00:00 AM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14

      COPENHAGEN, Denmark, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its second quarter 2024 financial results on Wednesday, August 14, 2024, before opening of the Nasdaq-CM. Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CEST/08:30 EDT presenting the update and results as well as taking questions. This event is free, open to the public and encouraged. To join the conference call, listen to the presentation and ask verbal questions, please register in advance v

      8/12/24 7:27:00 AM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fourth quarter and full year 2022 financial results and business update

      Evaxion presented promising data from its Phase 1/2a clinical trial of EVX-02 in patients with late-stage melanoma at the 2023 AACR meetingEVX-03, a DNA-based personalized cancer vaccine, is expected to have a CTA filing in Q3 2023 and start a Phase 1 trial in solid tumor patients in Q4 2023Recent collaborations with Pantherna Therapeutics GmbH (utilizing PIONEER™) and ExpreS2ion Biotechnologies ApS (utilizing RAVEN™) highlight the broad utility of Evaxion's differentiated AI platforms, which now includes the new ObsERVTM AI technology, which is designed to identify patient-specific viral targets from endogenous retroviruses (ERVs) known to be overexpressed in certain tumors$13 million in ca

      4/27/23 7:00:00 AM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Evaxion Biotech Announces Second Quarter 2022 Financial Results and Provides Business Update

      Expanded DNA oncology vaccine program into non-small cell lung cancer, NSCLCAnnounced successful production of personalized cancer immunotherapies for melanomaAnnounced gonorrhea as second bacterial product targetEnded second quarter with cash and cash equivalents of $25.3 millionEvaxion will host webcast and conference call today, August 10, at 8:30 am EDT COPENHAGEN, Denmark, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, announced today its second quarter 2022 financial results and provided an operational and business update. Lars Wegn

      8/10/22 7:00:00 AM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Evaxion Biotech to Host Q2 2022 Corporate Update Conference Call & Webcast on August 10

      COPENHAGEN, Denmark, July 29, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, announced today that it will present its second-quarter 2022 financial results on August 10 at 8.30 a.m. EDT. To dial-in for the conference call, please use the following details: US: +1-844-825-9789International: +1-412-317-5180Conference ID: 10169785 Alternatively to access the audio webcast, please visit the events page of Evaxion's website at:https://evaxion-biotech.com/news-and-events/events/default.aspx About EvaxionEvaxion Biotech A/S is a clinical-stage biotech

      7/29/22 5:46:36 PM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Evaxion Biotech Announces First Quarter 2022 Financial Results and Provides Business Update

      Received regulatory clearance in Australia to initiate phase 2b trial of lead cancer therapy EVX-01 targeting melanomaCompleted recruitment for Phase 1/2a clinical trial for EVX-02 with all patients receiving first doseAnnounced publication on personalized therapy with EVX-01 in patients with metastatic melanoma in the open-access, peer-reviewed medical science journal OncoImmunologyHosted Key Opinion Leader (KOL) webinar with acclaimed experts on metastatic melanoma and personalized cancer immunotherapiesEnded first quarter with cash and cash equivalents of $31.4 millionEvaxion will host webcast and conference call today, May 11, at 8:30 am EDT COPENHAGEN, Denmark, May 11, 2022 (GLOBE NE

      5/11/22 7:30:00 AM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Evaxion Biotech to Host Q1 2022 Corporate Update Conference Call & Webcast on May 11

      COPENHAGEN, Denmark, April 29, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, announced today that it will present its first-quarter 2022 financial results on May 11 at 8.30 a.m. EDT. To dial-in for the conference call, please use the following details: US: 1-877-407-0792International: 1-201-689-8263Conference ID: 13729241 Alternatively to access the webcast, please visit the events page of Evaxion's website at: https://evaxion-biotech.com/news-and-events/events/default.aspx About Evaxion Evaxion Biotech A/S is a clinical-stage AI-immunology™ p

      4/29/22 12:15:56 PM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Evaxion Biotech Announces Q2 2021 Financial Results and Provides Business Update

      Data reported in early July from EVX-01 clinical program showed a robust anti-tumor effect in combination with anti-PD-1 treatment for patients with metastatic melanoma, supporting advancement into a Phase 2b clinical trial Data also reported in early July from the EVX-02 clinical program in adjuvant melanoma support advancing into a Phase 2b clinical trialProduct candidate EVX-B1 is progressing through preclinical development as plannedReported preclinical proof of concept for the Adaptive and Intelligent Vaccine for a Rapid Response against Corona Viruses (AICoV) programCash reserves of $18.8 million as of June 30, 2021 are expected to provide funding of key programs into 2022 COPENHAGEN

      8/12/21 6:30:00 AM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Evaxion Biotech A/S Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Evaxion Biotech A/S

      SC 13G - Evaxion Biotech A/S (0001828253) (Subject)

      11/14/24 3:29:53 PM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Evaxion Biotech A/S

      SC 13G/A - Evaxion Biotech A/S (0001828253) (Subject)

      11/6/24 4:09:57 PM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Evaxion Biotech A/S

      SC 13G - Evaxion Biotech A/S (0001828253) (Subject)

      1/23/24 3:29:11 PM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Evaxion Biotech A/S SEC Filings

    See more
    • SEC Form 6-K filed by Evaxion Biotech A/S

      6-K - Evaxion Biotech A/S (0001828253) (Filer)

      5/5/25 8:45:29 AM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Evaxion Biotech A/S

      6-K - Evaxion Biotech A/S (0001828253) (Filer)

      4/29/25 8:30:32 AM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Evaxion Biotech A/S

      6-K - Evaxion Biotech A/S (0001828253) (Filer)

      4/28/25 8:16:21 AM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Evaxion Biotech A/S

      6-K - Evaxion Biotech A/S (0001828253) (Filer)

      4/10/25 8:15:36 AM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Evaxion Biotech A/S

      6-K - Evaxion Biotech A/S (0001828253) (Filer)

      4/7/25 6:00:16 AM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 20-F filed by Evaxion Biotech A/S

      20-F - Evaxion Biotech A/S (0001828253) (Filer)

      4/1/25 9:33:57 AM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Evaxion Biotech A/S

      6-K - Evaxion Biotech A/S (0001828253) (Filer)

      4/1/25 7:45:17 AM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Evaxion Biotech A/S

      6-K - Evaxion Biotech A/S (0001828253) (Filer)

      3/27/25 8:15:31 AM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Evaxion Biotech A/S

      6-K - Evaxion Biotech A/S (0001828253) (Filer)

      3/26/25 4:30:23 PM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B5 filed by Evaxion Biotech A/S

      424B5 - Evaxion Biotech A/S (0001828253) (Filer)

      3/26/25 4:01:53 PM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Evaxion Biotech A/S Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Evaxion Biotech upgraded by Ladenburg Thalmann with a new price target

      Ladenburg Thalmann upgraded Evaxion Biotech from Neutral to Buy and set a new price target of $8.00

      4/2/24 11:31:47 AM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Evaxion Biotech with a new price target

      H.C. Wainwright initiated coverage of Evaxion Biotech with a rating of Buy and set a new price target of $14.00

      2/12/24 6:37:53 AM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Oppenheimer initiated coverage on Evaxion Biotech A/S with a new price target

      Oppenheimer initiated coverage of Evaxion Biotech A/S with a rating of Outperform and set a new price target of $18.00

      3/8/21 8:22:12 AM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Oppenheimer initiated coverage on Evaxion Biotech with a new price target

      Oppenheimer initiated coverage of Evaxion Biotech with a rating of Outperform and set a new price target of $18.00

      3/2/21 11:06:10 AM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Oppenheimer initiated coverage on Evaxion Biotech A/S

      Oppenheimer initiated coverage of Evaxion Biotech A/S with a rating of Outperform

      3/2/21 8:24:17 AM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • LADENBURG THALM/SH SH initiated coverage on Evaxion Biotech A/S

      LADENBURG THALM/SH SH initiated coverage of Evaxion Biotech A/S with a rating of Buy

      3/2/21 8:22:02 AM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Evaxion Biotech A/S Leadership Updates

    Live Leadership Updates

    See more
    • Evaxion Biotech Appoints Dr. Birgitte Rønø as Chief Scientific Officer

      Dr. Rønø has developed Evaxion's pre-clinical and early clinical oncology pipelineNewly-created Chief Scientific Officer role strengthens Evaxion's leadership team COPENHAGEN, Denmark, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today it has promoted its Senior Director, Immuno-Oncology, Birgitte Rønø, Ph.D, to the newly-created position of Chief Scientific Officer, effective immediately. Lars Wegner, CEO of Evaxion, said: "As Senior Di

      9/21/21 8:34:52 AM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Evaxion Biotech Appoints Lars Holtug to the Board of Directors

      COPENHAGEN, Denmark, May 26, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today its shareholders elected Lars Holtug, a highly experienced financial professional with specific expertise in the healthcare industry, as a member of its Board of Directors. The vote was held at Evaxion's Annual General Meeting on May 25, 2021. Lars Holtug will also chair Evaxion's Audit Committee, taking over from Helen M. Boudreau, who chose not to stand for re-election for personal reasons. Marianne Søgaard, Chairwo

      5/26/21 8:30:00 AM ET
      $EVAX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care